Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7128022 | 0.90 | LMNA (0.44) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL7157791 | 0.86 | HTT (0.43) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL7134614 | 0.85 | NAMPT (0.48) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL7123777 | 0.82 | BCHE (0.43) | ALDH1A1KMT2AKDM4E | |
| SCHEMBL7132598 | 0.82 | NAMPT (0.36) | ALDH1A1KMT2ANAMPTMAPT | |
| SCHEMBL7122770 | 0.79 | HSD11B1 (0.32) | ALDH1A1KMT2APOLBKDM4EMAPT | |
| SCHEMBL7246746 | 0.77 | NOTUM (0.55) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL7132350 | 0.77 | KMT2A (0.47) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL7134615 | 0.76 | NAMPT (0.48) | LMNAALDH1A1MEN1KMT2AHTT | |
| SCHEMBL7133167 | 0.76 | KDM4E (0.51) | ALDH1A1MEN1KMT2AKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | claimed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | claimed |
| US-6555555-B1 | Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-29 | — | — | US | disclosed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | TPMT, CD47, THPO | LMNA 2985/4885ALDH1A1 3159/4885MEN1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.